Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Subfoveal Neovascularization.”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00288561
What this trial is testing

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration (ARMD)
Novartis
Testing effectiveness (Phase 2)Study completedNCT00239928
What this trial is testing

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Pfizer 61
Testing effectiveness (Phase 2)Study completedNCT00359164
What this trial is testing

Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.

Who this might be right for
Macular Degeneration
University of British Columbia 36
Testing effectiveness (Phase 2)Study completedNCT00426998
What this trial is testing

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

Who this might be right for
Choroidal NeovascularizationMacular Degeneration
Retinal Consultants Medical Group 30
Testing effectiveness (Phase 2)Ended earlyNCT02387957
What this trial is testing

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Who this might be right for
Age-Related Macular Degeneration
Ophthotech Corporation 63
Large-scale testing (Phase 3)Study completedNCT00150202
What this trial is testing

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

Who this might be right for
Macular Degeneration
Pfizer 90
Testing effectiveness (Phase 2)Study completedNCT00679445
What this trial is testing

Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy

Who this might be right for
Wet Age-related Macular Degeneration
NeoVista 20
Testing effectiveness (Phase 2)Ended earlyNCT00090532
What this trial is testing

The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
Pfizer 155
Testing effectiveness (Phase 2)Study completedNCT00284089
What this trial is testing

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Who this might be right for
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Novartis 88
Large-scale testing (Phase 3)Ended earlyNCT01944839
What this trial is testing

Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Who this might be right for
Age-Related Macular Degeneration
Ophthotech Corporation 619
Testing effectiveness (Phase 2)UnknownNCT00032396
What this trial is testing

Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Control Delivery Systems
Early research (Phase 1)Study completedNCT00503022
What this trial is testing

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Who this might be right for
Wet Age-Related Macular Degeneration
Novartis 20
Early research (Phase 1)Study completedNCT00749021
What this trial is testing

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Who this might be right for
Retinal Pigment Epithelial Detachment
Clement K. Chan 40
Large-scale testing (Phase 3)Study completedNCT00090623
What this trial is testing

RhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Genentech, Inc. 180
Testing effectiveness (Phase 2)Study completedNCT00259753
What this trial is testing

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
OPKO Health, Inc. 120
Large-scale testing (Phase 3)Study completedNCT00275821
What this trial is testing

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Who this might be right for
Age Related Macular Degeneration
Novartis 353
Testing effectiveness (Phase 2)UnknownNCT02599064
What this trial is testing

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Who this might be right for
Age-related Macular DegenerationSubfoveal Choroidal NeovascularizationSubretinal Scarring+1 more
RXi Pharmaceuticals, Corp. 9